Cell Pathways And Squibb Agree Joint Study

Cell Pathways, Inc. and Bristol-Myers Squibb Company plan to cooperate in supporting a clinical trial to study the combination of Aptosyn (exisulind) and TAXOL (paclitaxel) plus Paraplatin (carboplatin) as a first-line treatment for patients with advanced non- small cell lung cancer (NSCLC). This Phase I/II study is designed to evaluate escalating doses of Aptosyn in Read more about Cell Pathways And Squibb Agree Joint Study[…]

PPGx And Squibb Collaborate On Bioinformatics Software

PPGx, Inc. has announced that Bristol-Myers Squibb Company will incorporate its breakthrough GeneTrials Bioinformatics Platform into its pharmacogenomics research and development program. The agreement is part of PPGx’s GeneTrials Partner Program, a framework through which PPGx grants pharmaceutical and biotechnology companies early access to its bioinformatics technology and pharmacogenomics expertise. Through the program, PPGx software Read more about PPGx And Squibb Collaborate On Bioinformatics Software[…]

bristol myers squibb

Squibb Receives Approval For Glucovance

Bristol-Myers Squibb Company has announced U.S. FDA has approved Glucovance (Glyburide and Metformin HCl Tablets) for use, along with diet and exercise, as initial drug therapy for people with type 2 diabetes. The drug was also approved as second-line therapy for patients with type 2 diabetes who are currently taking either or a sulfonylurea and Read more about Squibb Receives Approval For Glucovance[…]

lexicon genetics incorporated

Lexicon Genetics Grants Bristol-Myers Squibb Sublicense

Lexicon Genetics Incorporated has granted a non-exclusive sublicense to Bristol- Myers Squibb Company for the use of certain aspects of Lexicon’s positive-negative selection and isogenic DNA technologies. Bristol-Myers Squibb will use the technology for the generation of knockout mice for internal research purposes to gain predictive information about gene products that are valid drug targets Read more about Lexicon Genetics Grants Bristol-Myers Squibb Sublicense[…]

bristol myers squibb

Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration

Exelixis, Inc. has extended and expanded its oncology research collaboration with Bristol-Myers Squibb Company under which the two companies will continue to identify and validate molecular targets implicated in cancer. The original agreement was established for a three-year term in July 2001. Subject to the terms of their amended agreement, Exelixis and Bristol-Myers Squibb have Read more about Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration[…]

Axys Announces Screening Agreement With Bristol-Myers Squibb

Axys Pharmaceuticals, Inc. announced that Axys Advanced Technologies, Inc. (AAT), its combinatorial chemistry subsidiary, entered into an agreement with Bristol-Myers Squibb Company (BMS) to provide them with diverse compounds for pharmaceutical screening. Axys will also provide BMS with enabling technologies for reproducing and expanding the library chemistries. This agreement provides for payments to AAT for Read more about Axys Announces Screening Agreement With Bristol-Myers Squibb[…]